{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:18:11Z","timestamp":1790518691118,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.neuropharm.2007.03.017","type":"journal-article","created":{"date-parts":[[2007,4,20]],"date-time":"2007-04-20T12:07:33Z","timestamp":1177070853000},"page":"1678-1684","source":"Crossref","is-referenced-by-count":144,"title":["Inhibition of glycogen synthase kinase-3\u03b2 protects dopaminergic neurons from MPTP toxicity"],"prefix":"10.1016","volume":"52","author":[{"given":"Wenya","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2007.03.017_bib1","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1073\/pnas.95.13.7659","article-title":"Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"95","author":"Ara","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib2","doi-asserted-by":"crossref","first-page":"45937","DOI":"10.1074\/jbc.M306268200","article-title":"Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418","volume":"278","author":"Bhat","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib3","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.04-1551fje","article-title":"Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death","volume":"18","author":"Chen","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0092-8674(01)00374-9","article-title":"Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition","volume":"105","author":"Dajani","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib6","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1038\/sj.onc.1204503","article-title":"Anti-mitotic properties of indirubin-3\u2032-monoxime, a CDK\/GSK-3 inhibitor: induction of endoreplication following prophase arrest","volume":"20","author":"Damiens","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0022-510X(87)90121-3","article-title":"Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mouse","volume":"77","author":"Donnan","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib8","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1523\/JNEUROSCI.20-24-09126.2000","article-title":"Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"20","author":"Eberhardt","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S1461145704004535","article-title":"AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test","volume":"7","author":"Gould","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbr.2005.04.011","article-title":"Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains","volume":"163","author":"Haobam","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.6610213","article-title":"Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice","volume":"225","author":"Heikkila","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/9035","article-title":"Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases","volume":"1","author":"Hoessel","year":"1999","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib13","first-page":"13","article-title":"Brain monoamines and parkinsonism","volume":"3","author":"Hornykiewicz","year":"1975","journal-title":"Natl. Inst. Drug Abuse Res. Monogr. Ser."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib14","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","article-title":"Biochemical aspects of Parkinson's disease","volume":"51","author":"Hornykiewicz","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1073\/pnas.93.7.2719","article-title":"Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I\/glycogen synthase kinase 3beta in brain","volume":"93","author":"Hoshi","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.brainres.2004.09.046","article-title":"Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice","volume":"1030","author":"Kato","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00001756-200504250-00016","article-title":"Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress","volume":"16","author":"King","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1074\/jbc.M002466200","article-title":"Indirubins inhibit glycogen synthase kinase-3 beta and CDK5\/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?","volume":"276","author":"Leclerc","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib20","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1212\/WNL.56.suppl_4.S26","article-title":"Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease","volume":"56","author":"Lee","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2007.03.017_bib21","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.1128\/MCB.20.24.9356-9363.2000","article-title":"Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta","volume":"20","author":"Li","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:TRAG.0000040039.44899.6f","article-title":"Overexpression of GSK3betaS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3beta transgenic mice","volume":"13","author":"Li","year":"2004","journal-title":"Transgenic Res."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-5793(02)03487-7","article-title":"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta","volume":"530","author":"Liu","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-2005-8104","article-title":"Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease","volume":"8","author":"Luna-Munoz","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib25","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1016\/j.febslet.2005.05.040","article-title":"Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart","volume":"579","author":"Mora","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1001958023096","article-title":"MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences","volume":"30","author":"Sedelis","year":"2000","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neures.2003.10.012","article-title":"SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease","volume":"48","author":"Wang","year":"2004","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2007.03.017_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0166-2236(98)01362-9","article-title":"Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias","volume":"22","author":"West","year":"1999","journal-title":"Trends Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390807000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390807000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T08:10:07Z","timestamp":1556352607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390807000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0028390807000962"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2007.03.017","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}